ZYBERNO
Stock Report
Updated Aug 26, 2026

Starling Oncology, Inc. (TOIIW)

Healthcare • NASDAQ

$0.06

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Starling Oncology, Inc. (TOIIW) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-4.4%)
Return on Capital (Capital Efficiency):CRITICAL (-13.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Starling Oncology, Inc. (TOIIW) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, TOIIW generated -$25.73M in Owner Earnings. Capital was deployed as follows: $9.00M returned via share buybacks, $3.91M invested in capital expenditures. Reinvestment rate: 19.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.06
Market Cap:$5.99M

Valuation Multiples (2)

P/S Ratio:0.01x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$171.74M

Price Action & Momentum (1)

% of 52-Week High:21.3%
B. Profitability Assessment

Return Metrics (4)

ROA:-21.5%
Reinvestment Rate:19.1%
Fundamental Growth Rate (g):-2.7%

Margin Analysis (3)

Operating Margin Ttm:-4.4%
Net Margin Ttm:-6.2%
Ebitda Margin:-2.9%

TTM Performance (2)

Operating Margin Ttm:-4.4%
Net Margin Ttm:-6.2%

Yield Metrics (2)

Earnings Yield:-$481.93
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:50.2%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):25.4%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.36x
Quick Ratio:1.15x
Cash Ratio:0.00x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-4.73x
Times Interest Earned:-4.73

Capital Structure (4)

Working Capital:34,051,000.00
Cash And Cash Equivalents:0.00
Long Term Debt:$79.87M
Net Debt:$165.76M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $587.24M
Linear Growth: 25.4%
📊 Click to view full TOIIW Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$26.09M

Bottom Line Performance (3)

-$36.29M
Income Before Tax:-$36.29M
Ebitda Ttm:-17,018,000.00

Operating Expenses (5)

Operating Expenses:613,334,000.00
R And D Expense:0.00
Sga Expense:111,446,000.00
Income Tax Expense:$0.00
Interest Expense:7,629,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:69.1%
Ebitda Margin:-2.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$178.23M
Current Assets:$128.99M
Ppe Net:10,583,000.00
Goodwill:7,230,000.00
Intangible Assets:$9.59M

Liability Structure (4)

Total Liabilities:203,147,000.00
Current Liabilities:94,939,000.00
Long Term Debt:$79.87M
Short Term Debt:$85.89M

Equity & Capital (3)

Equity:-$24.91M
Retained Earnings:-$283.70M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:66,349,000.00
Inventory:20,011,000.00
Accounts Payable:60,279,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,686,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$21.81M-$25.73M

Investment Activities (2)

Investing Cash Flow:-$1.04M
Capital Expenditures Ttm:3,914,000.00

Financing Activities (3)

Financing Cash Flow:-$28.00K
Dividends Paid Ttm:0.00
Stock Repurchase:9,000,000.00

Capital Transactions (3)

Common Stock Issuance:13,841,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:9,072,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.28
-$0.28
Earnings Per Share Ttm:-$0.35

Revenue & Cash Per Share (2)

Sales Per Share Ttm:5.70
Operating Cash Flow Per Share:-$0.24

Book Value & Capital (2)

Book Value Per Share:-$0.24
Cash Per Share:-999.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:3.48x
Working Capital Turnover Ttm:17.25x

Receivables Management (2)

Receivables Turnover Ttm:8.85x
Days Sales Outstanding Ttm:41.24

Inventory Management (2)

Inventory Turnover Ttm:29.35x
Days Inventory Outstanding Ttm:12.44

Payables & Cash Cycle (2)

Days Payable Outstanding:37.47
Cash Conversion Cycle:16.21
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$25.73M

Damodaran Growth Analysis (2)

Reinvestment Rate:19.1%
Fundamental Growth Rate (g):-2.7%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):25.4%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:TOIIW
Company Name:Starling Oncology, Inc.
Sector:Healthcare
Industry:Services-Offices & Clinics of Doctors of Medicine
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:103.03M
Shares Outstanding Basic:103.03M
Shares Outstanding Diluted:103.03M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-26 09:03:02 UTC
Data Timestamp:2026-08-26T09:03:02.961870
Scroll to Top